Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Élisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster et al. · The Lancet · 2011
Cited by 568 works. doi:10.1016/s0140-6736(11)60780-0
Authors
- Élisabeth Quoix
- Gérard Zalcman
- Jean-Philippe Oster
- Virginie Westeel
- Éric Pichon
- A. Lavolé
- Jérôme Dauba
- Didier Debieuvre
- Pierre-Jean Souquet
- Laurence Bigay-Game
- Éric Dansin
- M. Poudenx
- Olivier Molinier
- F. Vaylet
- Denis Moro‐Sibilot
- Dominique Herman
- Jaafar Bennouna
- Jean Trédaniel
- A Ducoloné
- Marie-Paule Lebitasy
References
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
- Global cancer statistics
- Reporting results of cancer treatment
- Global Cancer Statistics, 2002
- Population-Based Norms for the Mini-Mental State Examination by Age and Educational Level
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- Comorbidity and functional status are independent in older cancer patients.
- Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer